Ultragenyx Pharmaceutical, Inc. Stock News

Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Erik Harris - Executive VP & Chief Commercial Officer Howard Horn - Executive VP of Corporate Strategy & CFO Eric Crombez - Chief Medical Officer & Executive VP Con...

Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price Proceeds to fund four expected launches, setting the company up for the next stage of growth NOVATO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ...

NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 4, 2025, to discuss its financial results and corporate update for...

NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 20,317 restricted stock units of the company's common stock to 17 newly hired non-executive officers of the company. The awards were approved ...

NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 62,232 shares of common stock of the company and 34,564 restricted stock units of the ...

NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg. Mr. Olson will be responsible for leading the company's business development, corporate development and allian...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Bank of America Global Healthcare Conference 2025 September 23, 2025 6:35 AM EDT Company Participants Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Tazeen Ahmad - BofA Securities, Research Division Presentation Tazeen Ahmad BofA Securities, Research Division Good morning to everybody listening in. Welcome to the Ba...

NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,561 restricted stock units of the company's common stock to 17 newly hired non-executive officers of the company. The awards were approved...